PubRank

Nikki P Lee

Author PubWeight™ 38.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012 4.07
2 Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 2014 3.31
3 Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013 2.12
4 Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012 1.50
5 DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem 2011 1.40
6 Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 2007 1.39
7 Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009 1.32
8 Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012 1.10
9 Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005 1.06
10 Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Cancer 2011 1.03
11 HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics 2013 1.02
12 Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol 2007 1.00
13 Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol 2011 0.94
14 Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. J Neurooncol 2011 0.94
15 Cytoplasmic Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage. World J Surg 2012 0.94
16 Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol 2013 0.93
17 Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm). J Proteome Res 2010 0.93
18 Heat shock proteins in cancer: signaling pathways, tumor markers and molecular targets in liver malignancy. Protein Pept Lett 2009 0.87
19 Circulating markers for prognosis of hepatocellular carcinoma. Expert Opin Med Diagn 2013 0.86
20 Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. J Neurooncol 2012 0.86
21 Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. Liver Int 2007 0.86
22 Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2. Dig Dis Sci 2014 0.85
23 Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma. PLoS One 2013 0.84
24 Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One 2011 0.83
25 Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells. Biosci Trends 2014 0.82
26 Hepatic tight junctions: from viral entry to cancer metastasis. World J Gastroenterol 2010 0.81
27 Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma. Int J Hepatol 2012 0.79
28 Tumor necrosis factor-alpha-induced protein 1 and immunity to hepatitis B virus. World J Gastroenterol 2005 0.78
29 Clinicopathologic and gene expression parameters predict liver cancer prognosis. BMC Cancer 2011 0.78
30 Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. Expert Rev Mol Diagn 2014 0.77
31 Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma. Med Oncol 2011 0.77
32 Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology 2008 0.76
33 Biomarkers for early detection of liver cancer: focus on clinical evaluation. Protein Pept Lett 2009 0.76
34 Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy. J Clin Microbiol 2006 0.76
35 Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma. Med Oncol 2012 0.76
36 The use of small peptides in the diagnosis and treatment of hepatocellular carcinoma. Protein Pept Lett 2009 0.75